About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: XENE
- Previous Close: $7.75
- 50 Day Moving Average: $8.19
- 200 Day Moving Average: $8.05
- 52-Week Range: $5.65 - $8.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.01
- P/E Growth: -0.09
- Market Cap: $138.67M
- Outstanding Shares: 17,893,000
- Beta: 1.44
- Net Margins: -449.72%
- Return on Equity: -34.72%
- Return on Assets: -32.94%
Companies Related to Xenon Pharmaceuticals:
- Current Ratio: 17.97%
- Quick Ratio: 17.97%
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 12 month price objectives for Xenon Pharmaceuticals' shares. Their predictions range from $13.00 to $20.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $16.30 in the next year.
When will Xenon Pharmaceuticals announce their earnings?
Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Xenon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:
According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (12/22/2016)
Jefferies Group LLC analysts commented, "XENE continues to make progress with PII data for XEN801 for mod-to-severe acne on-track for Q4’16 and PIIb data for postherpetic neuralgia for TV45070 in H1’17. This morning, Dermira reported positive PIIb data on DRM01 in acne, which we believe has a favorable read-thru for XEN801 since it operates on the same pathway (DRM01 more upstream). XEN801 may be able to derive greater activity given the dual mechanism that also induces apoptosis in sebocytes. XEN801 PIIa Data in Moderate-to-Severe Acne Expected in Q4: XEN801, a SCD1 inhibitor, is a potential tx of moderate-to-severe acne and is in a PII trial following positive PI data showing safety and tolerability, as well as good skin exposure and low systemic exposure. As previously disclosed, the PII trial is enrolling ~150 pts with moderate-to-severe acne who will apply XEN801 to the face for 12 wks, w/ 4-wk follow-up. The 1 EP will be percent change in total lesion count, including inflammatory and non-inflammatory, and topline data could be in Q4. This morning, we note that Dermira (DERM, NC) reported positive PIIb data for DRM01 in mod-to-severe acne, which we believe has a favorable read- thru to XEN801 since it operates on the same pathway (DRM01 is more upstream). XEN801 may be able to derive greater activity given the dual mechanism that also induces apoptosis in sebocytes." (5/11/2016)
Who owns Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (5.59%), Perceptive Advisors LLC (4.14%), Opaleye Management Inc. (2.26%), Interwest Venture Management Co. (1.79%), Novo A S (0.71%) and Renaissance Technologies LLC (0.64%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Ian Mortimer and Y Paul Goldberg.
Who sold Xenon Pharmaceuticals stock? Who is selling Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Opaleye Management Inc. and Scotia Capital Inc..
Who bought Xenon Pharmaceuticals stock? Who is buying Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Interwest Venture Management Co. and Renaissance Technologies LLC.
How do I buy Xenon Pharmaceuticals stock?
Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Xenon Pharmaceuticals stock cost?
One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $7.75.